A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

This Phase II trial tests two combinations of immunotherapy drugs (AK104 or AK112) with a targeted drug (TT-00420) in people with advanced liver cancer (hepatocellular carcinoma) who have not previously received systemic treatment. **You may be eligible if:** - You are between 18 and 75 years old - Your liver cancer has been confirmed by biopsy or meets diagnostic criteria - Your disease is at an advanced stage (BCLC stage C) or stage B unsuitable for local curative treatment - You have not previously received systemic treatment for liver cancer - You have adequate liver function, organ function, and overall health status (ECOG 0 or 1) - Your hepatitis B or C infection is clinically controlled **You may NOT be eligible if:** - You have a rare subtype of liver cancer (e.g., fibrolamellar, sarcomatoid, or cholangiocarcinoma) - You have had another cancer in the past 3 years - You have a history of liver-related brain confusion (hepatic encephalopathy) - You have significant fluid around the heart, lungs, or abdomen - You have active tuberculosis, HIV, or syphilis - You have had esophageal or stomach variceal bleeding in the past 6 months - Your liver tumor takes up more than 50% of your liver Talk to your doctor to see if this trial is right for you.